Rocket Pharmaceuticals and Stanford University announces strategic research collaboration
Rocket Pharma and the Stanford University School of Medicine today announced a strategic collaboration to support the advancement of Fanconi Anemia and Pyruvate Kinase Deficiency gene therapy research. The LVV-based gene therapy program for PKD is currently in preclinical development in Europe. May 17, 2018